Why Scientists Are Worried About a New Alzheimer's Drug Up for FDA Approval
The fate of an experimental dementia drug will be decided within days. On Monday, the Food and Drug Administration is set to announce whether it will approve Biogen's antibody-based therapy aducanumab as a treatment for Alzheimer's disease-the first intended to slow down the progression of the incurable ailment. But...